Molecular Partners Ag Stock Cash Flow From Operations
| MLLCF Stock | USD 4.22 0.00 0.00% |
Fundamental analysis of Molecular Partners allows traders to better anticipate movements in Molecular Partners' stock price by examining its financial health and performance throughout various phases of its business cycle.
Molecular |
Molecular Partners AG Company Cash Flow From Operations Analysis
Molecular Partners' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Molecular Partners Cash Flow From Operations | (90.95 M) |
Most of Molecular Partners' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Molecular Partners AG has (90.95 Million) in Cash Flow From Operations. This is 117.25% lower than that of the Healthcare sector and 245.47% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 109.36% higher than that of the company.
Molecular Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in cash flow from operations category among its peers.
Molecular Fundamentals
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (41.92 M) | |||
| Shares Outstanding | 36.04 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Shares Owned By Institutions | 45.00 % | |||
| Price To Earning | 1.74 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| Gross Profit | (45.96 M) | |||
| EBITDA | (60.67 M) | |||
| Net Income | (63.78 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 5.15 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.37 X | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.82 X | |||
| Number Of Employees | 163 | |||
| Beta | 0.62 | |||
| Market Capitalization | 237.9 M | |||
| Total Asset | 172.67 M | |||
| Z Score | 27.6 | |||
| Net Asset | 172.67 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| RYCEY | Rolls Royce Holdings | |
| VSAT | ViaSat Inc | |
| CIG | Companhia Energetica de | |
| ATEX | Anterix | |
| BBAI | BigBearai Holdings |
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.